yahoo_financeOriginal article
Humacyte Says US FDA Accepted IND for Human Trial of Coronary Tissue Engineered Vessel in Surgery
Phase 1approvedCoronary Tissue Engineered VesselPositive
AI Analysis
Summary
Humacyte announced that the US FDA accepted its IND application to initiate a human clinical trial for its tissue engineered coronary vessel designed for surgical use.
Clinical Trial Data
Phase
1
Outcome Details
US FDA accepted IND application
Importance:6/10
Sentiment:
0.70
IND acceptancetissue engineeringcardiovascularFDA approvalclinical trial
Related Companies
Read the original article
Published by yahoo_finance on July 27, 2026 12:54 PM